For the Inventor, By the Inventor

Enter assignee name

Impact Therapeutics, Inc.

USPTO Granted Patents = 11

EPO Patents = 9

Forward Citations = 25

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Ye Edward Tian (8 out of 16 patents)

Sui Xiong Cai (5 out of 11 patents)

Suixiong Cai (5 out of 9 patents)

4. Qingbing Xu (4 out of 4 patents)

5. Lizhen Wu (4 out of 5 patents)

6. Lijun Liu (4 out of 5 patents)

7. Yangzhen Jiang (4 out of 4 patents)

8. Guoxiang Wang (4 out of 4 patents)

9. Feng Yin (4 out of 5 patents)

10. Chengyun Gu (4 out of 4 patents)

11. Xiuhua Hu (4 out of 4 patents)

12. Xiaozhu Wang (4 out of 10 patents)

13. Sishun Kang (4 out of 4 patents)

14. Shengzhi Chen (4 out of 4 patents)

15. Haijun Dong (3 out of 5 patents)

11 patents: Sort by Forward Citations

1. 11358955 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2022-06-14),

2. 11179392 - Solid pharmaceutical formulation of PARP inhibitors and use thereof (2021-11-23),

3. 10874670 - Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof (2020-12-29),

4. 10703759 - 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones (2020-07-07),

5. 10676468 - N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof (2020-06-09),

6. 10562889 - Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones (2020-02-18),

7. 10316027 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2019-06-11),

8. 9926304 - 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof (2018-03-27),

9. 9290460 - [object Object] (2016-03-22),

10. 9102631 - 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof (2015-08-11),

11. 9090568 - Quinazolinediones and their use (2015-07-28),

Impact Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for the treatment of cancer. We aim to provide novel solutions that will have a positive impact on patients' lives. Our team of experienced scientists and researchers is dedicated to discovering and developing breakthrough drugs that target specific cancer-related molecular pathways. Through our cutting-edge research and collaborations, we strive to bring transformative treatments to cancer patients worldwide.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

11 Patents

#40 in Nanjing

#2,539 in China

#51,671 in the World

Impact Therapeutics, Inc.

Forward Citations = 25

27 inventors:

Ye Edward Tian (8 out of 16 patents)

Sui Xiong Cai (5 out of 11 patents)

Suixiong Cai (5 out of 9 patents)

4. Qingbing Xu (4 out of 4 patents)

5. Lizhen Wu (4 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…